Type I collagen and collagen mimetics as angiogenesis promoting superpolymers

Current Pharmaceutical Design

Volumn 13, Issue 35, 2007, Pages 3608-3621

  Twardowski, T ^a   Fertala, A ^b   Orgel, J P R O ^c   San Antonio, James D ^b  

^a WIDENER UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Illinois Institute of Technology   (United States)

Author keywords

Angiogenesis; Integrins; Recombinant collagens; Superpolymer; Tissue engineering; Type I collagen

Indexed keywords

ALGINIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CARRAGEENAN; CELL SURFACE RECEPTOR; CELLULOSE; CHITIN; CHONDROITIN SULFATE; COLLAGEN FIBRIL; COLLAGEN TYPE 1; ELASTIN; FIBRIN; GLYCOSAMINOGLYCAN; HEPARIN; HYALURONIC ACID; INTEGRIN RECEPTOR; KERATIN; MACROGOL; POLY(ORTHO ESTER); POLYESTER; POLYLYSINE; POLYMACON; POLYMER; POLYSACCHARIDE; TUBULIN; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2;

ANGIOGENESIS; BINDING SITE; BIOENGINEERING; CANCER GROWTH; CHEMICAL STRUCTURE; CUTICLE; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GENETIC ENGINEERING; HALF LIFE TIME; HEMANGIOMA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; METASTASIS; MICROVASCULATURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SILK; STRUCTURE ACTIVITY RELATION; TISSUE BLOOD FLOW; TISSUE ENGINEERING; TISSUE REGENERATION; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; BIOCOMPATIBLE MATERIALS; COLLAGEN TYPE I; FIBRIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE ENGINEERING;

EID: 36949016403     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782794176     Document Type: Review

References (116)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
3. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-33.
4. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-107.
5. Hay ED, editor. Cell biology of extracellular matrix. New York and London: Plenum Press 1991.
6. San Antonio JD, Iozzo RV. The two-phase model for angiogenesis regulation by the extracellular matrix. In: Shepro D, Ed. Encylopedia of the Microvasculature: Elsevier Science, USA 2006; 127-36.
7. Piez KA, Reddi AH. Extracellular matrix biochemistry. New York: Elsevier 1984.
8. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403-34.
9. Di Lullo GA, Sweeney SM, Korkko J, Ala-Kokko L, San Antonio JD. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J Biol Chem 2002; 277: 4223-31.
10. Sweeney SM, Orgel JP, Fertala A, McAuliff J, Turner KR, Di Lullo GA, et al. Cell and matrix interaction domains on the collagen fibril. Submitted 2007.
11. Yamada KM. Integrin signaling. Matrix Biol 1997; 16: 137-41.
12. Calderwood DA, Shattil SJ, Ginsberg MH. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. J Biol Chem 2000; 275: 22607-10.
13. Davis GE, Camarillo CW. An alpha2 beta1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 1996; 224: 39-51.
14. Sweeney SM, DiLullo G, Slater SJ, Martinez J, Iozzo RV, Lauer-Fields JL, et al. Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J Biol Chem 2003; 278: 30516-24.
15. Vargas FF, Osorio HM, Basilio C, De Jesus M, Ryan US. Enzymatic lysis of sulfated glycosaminoglycans reduces the electrophoretic mobility of vascular endothelial cells. Membr Biochem 1990; 9: 83-9.
16. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108: 349-55.
17. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1997; 1: 25-34.
18. Schlessinger J. Direct binding and activation of receptor tyrosine kinases by collagen. Cell 1997; 91: 869-72.
19. Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F, Pawson T. Discoidin domain receptor 1 is activated independently of beta(1) integrin. J Biol Chem 2000; 275: 5779-84.
20. Scott JE. Proteoglycan-fibrillar collagen interactions. Biochem J 1988; 252: 313-23.
21. Dzamba BJ, Wu H, Jaenisch R, Peters DM. Fibronectin binding site in type I collagen regulates fibronectin fibril formation. J Cell Biol 1993; 121: 1165-72.
22. Huq NL, Loganathan A, Cross KJ, Chen YY, Johnson NI, Willetts M, et al. Association of bovine dentine phosphophoryn with collagen fragments. Arch Oral Biol 2005; 50: 807-19.
23. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007; 28: 209-21.
24. Chapman JA. The staining pattern of collagen fibrils. I. An analysis of electron micrographs. Connect Tiss Res 1974; 2: 137-50.
25. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell 2000; 101: 47-56.
26. Xu Y, Gurusiddappa S, Rich RL, Owens RT, Keene DR, Mayne R, et al. Multiple binding sites in collagen type I for the integrins {alpha} {sub1} {beta} {sub1} and {alpha} {sub2} {beta} {sub1}. J Biol Chem 2000; 275: 38981-9.
27. Reyes CD, Garcia AJ. Alpha2beta1 integrin-specific collagen-mimetic surfaces supporting osteoblastic differentiation. J Biomed Mater Res A 2004; 69: 591-600.
28. Baronas-Lowell D, Lauer-Fields JL, Fields GB. Induction of endothelial cell activation by a triple helical alpha2beta integrin ligand, derived from type I collagen alpha1(I)496-507. J Biol Chem 2004; 279: 952-62.
29. Scott JE, Tenni R. Osteogenesis imperfecta mutations may probe vital functional domains (e.g. proteoglycan binding sites) of type 1 collagen fibrils. Cell Biochem Funct 1997; 15: 283-6.
30. Orgel JP, Irving TC, Miller A, Wess TJ. Microfibrillar structure of type I collagen in situ. Proc Natl Acad Sci USA 2006; 103: 9001-5.
31. Silver FH, Trelstad R.L. Type I collagen in solution. Structure and properties of fibril fragments. J Biol Chem 1980; 255: 9427-33.
32. Zimmermann BK, Pikkarainen J, Fietzek PP, Kuhn K. Cross-linkages in collagen. Demonstration of three different intermolecular bonds. Eur J Biochem 1970; 16: 217-25.
33. Weiner S, Traub W. Organization of hydroxyapatite crystals within collagen fibrils. FEBS Lett 1986; 206: 262-6.
34. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta: a quantitative assay of angiogenesis in vitro. Lab Invest 1990; 63: 115-22.
35. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983; 97: 1648-52.
36. Jackson CJ, Jenkins KL. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 1991; 192: 319-23.
37. Jackson CJ, Giles I, Knop A, Nethery A, Schrieber L. Sulfated polysaccharides are required for collagen-induced vascular tube formation. Exp Cell Res 1994; 215: 294-302.
38. Kamei M, Saunders WB, Bayless KJ, Dye L, Davis GE, Weinstein BM. Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 2006; 442: 453 -6.
39. Cotta-Pereira G, Sage H, Bornstein P, Ross R, Schwartz S. Studies of morphololically atypical ("sprouting") cultures of bovine aortic endothelial cells. Growth characteristics and connective tissue protein synthesis. J Cell Physiol 1980; 102: 183-91.
40. Levene CI, Bartlet C, Heale G. Phenotypic changes in morphology and collagen polymorphism of cultured bovine and porcine aortic endothelium. Atherosclerosis 1984; 52: 59-71.
41. Iruela-Arispe ML, Hasselaar P, Sage H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab Invest 1991; 64: 174-86.
42. Fouser L, Iruela-Arispe L, Bornstein P, Sage EH. Transcriptional activity of the α1(I)-collagen promoter is correlated with the formation of capillary-like structures by endothelial cells in vitro. J Biol Chem 1991; 266: 18345-51.
43. Ingber DE, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988; 59: 44-51.
44. Seandel M, Noack-Kunnmann K, Zhu D, Aimes RT, Quigley JP. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 2001; 97: 2323-32.
45. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
46. Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res 1999; 90: 647-54.
47. Senger DR, Petruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 2002; 160: 195-204.
48. Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149-60.
49. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, Gopal S, et al. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97: 10454-9.
50. Yang J, Boerm M, McCarty M, Bucana C. Fidler U, Zhuang Y, et al. Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 2000; 24: 309-13.
51. Ivaska J, Reunanen H, Westermarck J, Koivisto L, Kahari VM, Heino J. Integrin alpha2betal mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol 1999; 147: 401-16.
52. Klekotka PA, Santoro SA, Zutter MM. alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. J Biol Chem 2001; 276: 9503-11.
53. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998; 111: 3621-31.
54. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin aVB3 by an organic molecule inhibits aniogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001; 98: 119-24.
55. Liu Y, Senger DR. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. FASEB J 20,04; 18: 457-68.
56. Drake CJ, Davis LA, Little CD. Antibodies to beta 1-integrins cause alterations of aortic vasculogenesis, in vivo. Dev Dyn 1992; 193: 83-91.
57. Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DG, Mousa SA, Tuszynski GP, et al. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res 2003; 63: 2020-3.
58. Senger DR, Claffey KP, Benes JE, Petruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 1997; 94: 13612-7.
59. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003; 278: 423-849.
60. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004; 166: 97-109.
61. Siljander PR, Hamaia S, Peachey AR, Slatter DA, Smethurst PA, Ouwehand WH, et al. Integrin activation state determines selectivity for novel recognition sites in fibrillar collagens. J Biol Chem 2004; 279: 47763-72.
62. Perret S, Eble JA, Siljander PR, Merle C, Farndale RW, Theisen M, et al. Prolyl hydroxylation of collagen type I is required for efficient binding to integrin alpha 1 beta 1 and platelet glycoprotein VI but not to alpha 2 beta 1. J Biol Chem 2003; 278: 29873-9.
63. Wang H, Fertala A, Ratner BD, Sage EH, Jiang S. Identifying the SPARC binding sites on collagen I and procollagen I by atomic force microscopy. Anal Chem 2005; 77: 6765-71.
64. Vernon RB, Lara SL, Drake CJ, Iruela-Arispe L, Angello JC, Little CD, et al. Organised type I collagcn influences endothelial patterns during "spontaneous angiogenesis in vitro": planar cultures as models of vascular development. In Vitro Cell Dev Biol 1995; 31: 120-31.
65. Weisel JW. Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 1986; 50: 1079-93.
66. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24.
67. Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J. Fibrin II induces endothelial cell capillary tube formation. J. Cell Biol. 1995; 130: 207-15.
68. Bach TL, Barsigian C, Yaen CH, Martinez J. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 1998; 273: 30719-28.
69. Yannas I. Biologically active scaffolds based on collagen-GAG copolymers. In: Ma PX, Elisseeff J, Eds. Scaffolding in tissue engineering. Boca Raton Florida: CRC Press 2006; 3-12.
70. Tessmar JKV, Holland TA, Mikos AG. Salt leaching for polymer scaffolds: laboratory-scale manufacture of cell carriers. In: Ma PX, Elisseeff J, Eds. Scaffolds for tissue engineering. Boca Raton: CRC Press 2006; 111-24.
71. Chen VJ, Ma PX. Polymer phase separation. In: Ma PX, Elisseeff J, Eds. Scaffolding in tissue engineering. Boca Raton: CRC Press 2006; 125-37.
72. Huang Y-C, Mooney D. Gas foaming to fabricate polymer scaffolds in tissue engineering. In: Ma PX, Elisseeff J, Eds. Scaffolds for tissue engineering. Boca Raton: CRC Press 2006; 155-67.
73. Khademhosseini A, Langer R, Borenstein J, Vacanti J. Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci USA 2006; 103: 2480-7.
74. Chu T-MG. Solid freeform fabrication of tissue engineering scaffolds. In: Ma PX, Elisseeff J, Eds. Scaffolds for tissue engineering. Boca Raton: CRC Press 2006; 139-53.
75. Fourné F. Synthetic fibers: machines and equipment, manufacture, properties. munich: Carl Hanser Verlag 1999.
76. Unger RE, Peters K, Huang Q, Funk A, Paul D, Kirkpatrick CJ. Vascularization and gene regulation of human endothelial cells growing on porous polyethersulfone (PES) hollow fiber membranes. Biomaterials 2004; 26: 3461-9.
77. Santos MI, Fuchs S, Gomes ME, Unger RE, Reis RL, Kirkpatrick CJ. Response of micro- and macrovascular endothelial cells to starch-based fiber meshes for bone tissue engineering. Biomaterials 2007; 28: 240-8.
78. Fertala A, Sieron AL, Ganguly A, Li SW, Ala-Kokko L, Anumula KR, et al. Synthesis of recombinant human procollagen II in a stably transfected tumour cell line (HT1080). Biochem J 1994; 298: 31-7.
79. Geddis AE, Prockop DJ. Expression of human COL1A1 gene in stably transfected HT1080 cells: The production of a thermostable homotrimer of type I collagen in a recombinant system. Matrix 1993; 13: 399-405.
80. Humtsoe JO, Kim JK, Xu Y, Keene DR, Hook M, Lukomski S, et al. A streptococcal collagen-like protein interacts with the alpha2beta1 integrin and induces intracellular signaling. J Biol Chem 2005; 280: 13848-57.
81. Myllyharju J. Recombinant collagen trimers from insect cells and yeast. Methods Mol Biol 2000; 139: 39-48.
82. Olsen DR, Leigh SD, Chang R, McMullin H, Ong W, Tai E, et al. Production of human type I collagen in yeast reveals unexpected new insights into the molecular assembly of collagen trimers. J Biol Chem 2001; 276: 24038-43.
83. Ruggiero F, Exposito JY, Bournat P, Gruber V, Perret S, Comte J, et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett 2000; 469: 132-6.
84. Toman PD, Chisholm G, McMullin H, Giere LM, Olsen DR, Kovach RJ, et al. Production of recombinant human type 1 procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae. J Biol Chem 2000; 275: 23303-9.
85. Majsterek I, McAdams E, Adachi E, Dhume ST, Fertala A. Prospects and limitations of the rational engineering of fibrillar collagens. Protein Sci 2003; 12: 2063-72.
86. Arnold WV, Fertala A, Sieron AL, Hattori H, Mechling D, Bachinger HP, et al. Recombinant procollagen II: Deletion of D period segments identifies sequences that are required for helix stabilization and generates a temperature-sensitive N-proteinase cleavage site. J Biol Chem 1998; 273: 31822-8.
87. Fertala A, Han WB, Ko FK. Mapping critical sites in collagen II for rational design of gene-engineered proteins for cell-supporting materials. J Biomed Mater Res 2001; 57: 48-58.
88. Ito H, Rucker E, Steplewski A, McAdams E, Brittingham RJ, Alabyeva T, et al. Guilty by association: some collagen II mutants alter the formation of ECM as a result of atypical interaction with fibronectin. J Mol Biol 2005; 352: 382-95.
89. Steplewski A, Hintze V, Fertala A. Molecular basis of organization of collagen fibrils. J Struct Biol 2007; 157: 297-307.
90. Prockop DJ, Fertala A. Inhibition of the self-assembly of collagen I into fibrils with synthetic peptides. Demonstration that assembly is driven by specific binding sites on the monomers. J Biol Chem 1998; 273: 15598-604.
91. Prockop DJ, Fertala A. The collagen fibril: the almost crystalline structure. J Struct Biol 1998; 273: 111-8.
92. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002; 21: 4765-77.
93. Yin H, Gerlach LO, Miller MW, Moore DT, Liu D, Vilaire G, et al. Arylamide derivatives as allosteric inhibitors of the integrin alpha2beta1/type I collagen interaction. Bioorg Med Chem Lett 2006; 16: 3380-2.
94. Vincent J. Structural biomaterials. Revised ed. Princeton: Princeton University Press 1990.
95. Ehrenfreund-Kleinman T, Golenser J, Domb AJ. Polysaccharide scaffolds for tissue engineering. In: Ma PX, Elisseeff J, Eds. Scaffolding for tissue engineering. Boca Raton: CRC Press 2006; 27-44.
96. Ma PX, Langer R. Fabrication of biodegradable polymer foams for cell transplantation and tissue engineering. In: Morgan J, Yarmush M, Eds. Tissue engineering methods and protocols. Totowa, New Jersey: Humana Press 1999; 47-56.
97. Park JB. Biomaterials and introduction. New York: Plenum Press 1980.
98. Silver FH, Christiansen DL. Biomaterials science and biocompatibility. New York: Springer Verlag 1999.
99. Ambrosio L, Peluso G, Davis P. Biomaterials and their biocompatibilities. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszemski MJ, Grosser JD, Eds. Human biomaterials applications. Totowa New Jersey: Humana Press 1996; 3-17.
100. Chen H, He Y, Qiang D. Fine structure-property relationships of biomedical ion-containing polymers. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszemski MJ, Gresser JD, Eds. Human biomaterials applications. Totawa New Jersey: Humana Press 1996; 59-88.
101. La Barre S, Boisson-Vidal C. Blood-compatible bioactive polymers. In: Wise DL, Trantolo DJ, Lewandrowski K-U, Gresser JD, Cattaneo MV, Yaszemski MJ, Eds. Biomaterials engineering and devices. Totowa New Jersey: Humana Press 2000; 25-47.
102. Park KD, Kim YH, Lee WK. Novel modification of bioprosthetic tissue for improved calcification resistance. In: Wise DL, Trantolo DJ, Lewandrowski K-U, Gresser JD, Cattaneo MV, Yaszemski MJ, Eds. Biomaterials engineering and devices. Totowa New Jersey: Humana Press 2000; 49-56.
103. Bowlin GL, Schmidt SP, Rittgers SE, Pawlowski KJ. Endothelialization of vascular prostheses. In: Wise DL, Trantolo DJ, Lewandrowski K-U, Grosser JD, Cattaneo MV, Yaszemski MJ, Eds. Biomaterials engineering and devices. Totowa New Jersey: Humana Press 2000; 85-118.
104. Nathan A, Kohn J. Amino acid derived polymers. In: Shalaby SW, Ed. Biomedical polymers. Cincinnnatti: Hanser/Gardner 1994; 117-51.
105. Urry DW, Hugel T, Seitz M, Gaub HE, Sheiba L, Des J, et al. Elastin: a representative ideal protein elastomer. Philos Trans R Soc London Part B 2002; 169-84.
106. Cardin AD, Weintraub HJR. Molecular modelling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 21-32.
107. Verrecchio A, Germann M, Schick B, Kung B, Twardowski T, San Antonio JD. Design of peptides with high affinity for heparin and endothelial cell proteoglycans. J Biol Chem 2000; 275: 7701-7.
108. Ostroha J, San Antonio JD, Germann MW, Twardowski TE. Polymeric vascular graft design for endothelialization. Medical Plastics Technology News. Fall-Winter 2001-2002; 7-13.
109. Scopelianos. Polyphosphazenes as new biomaterials. In: Shalaby SW, Ed. Biomedical polymers. cincinnatti: Hanser/Verlag 1994; 153-71.
110. Shalaby SW, Johnson RA. Synthetic absorbable polyesters. In: Shalaby SW, Ed. Biomedical polymers. cincinnati: Hanser/Gardner 1994; 1-34.
111. Gross RA. Bacterial polyesters: structural variability in microbial synthesis. In: Shalaby SW, Ed. Biomedical polymers. Cincinnatti: Hanser/ Verlag 1994; 173-88.
112. Heller J, Daniels AU. Poly(ortho esters). In: Shalaby SW, Ed. Biomedical polymers. Cincinnatti: Hanser/Gardner 1994; 35-67.
113. Kaplan DL, Wiley BJ, Mayer JM, Arcidiacono S, Keith J, Lombardi SJ, et al. Biosynthetic polysaccharides. In: Shalaby SW, Ed. Biomedical polymers. cincinnatti: Hanser/Verlag 1994; 189-212.
114. Chew SY, Wen Y, Dzenis Y, Leong KW. The role of electrospinning in the emerging field of nanomedicine. Curr Pharm Des 2006; 12(36): 4751-70.
115. Parissis J, Filippatos G, Adamopoulos S, Li X, Kremastinos DT, Uhal BD. Hematopoietic colony stimulating factors in cardiovascular and pulmonary remodeling: promoters or inhibitors? Curr Pharm Des 2006; 12(21): 2699-99.
116. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007; 13(20): 2074-86.